Division of Pharmaceutical, Administrative and Social Sciences, Duquesne University School of Pharmacy, Pittsburgh, PA, USA.
Division of Pharmacy Practice, Duquesne University School of Pharmacy, Pittsburgh, PA, USA.
Expert Rev Anti Infect Ther. 2024 Nov;22(11):925-934. doi: 10.1080/14787210.2024.2400703. Epub 2024 Sep 8.
Infections with Acinetobacter baumannii-calcoaceticus complex (ABC) pose difficulty for clinicians given a limited arsenal of effective antimicrobials. Sulbactam/durlobactam provides a novel treatment option for patients experiencing hospital- or ventilator-acquired pneumonia with susceptible strains.
This review provides a comprehensive discussion of sulbactam/durlobactam, including basic characteristics, in vitro activity, and clinical trial data supporting its use for the treatment of ABC. Manufacturer's data, published literature to date, and conference data are utilized in this review.
Sulbactam/durlobactam offers clinicians a new and effective treatment option for resistant ABC infection. Sulbactam, when combined with durlobactam, displays enhanced potency against ABC isolates, which has translated into positive clinical outcomes observed in clinical trials and post-marketing case studies. Although overall treatment indications and clinical experience are limited to date, sulbactam/durlobactam offers a familiar and favorable safety profile in comparison with alternative agents. Factors associated with use of combination antibiotic therapy, availability of commercial drug susceptibility testing, and cost-effectiveness are all currently key considerations for sulbactam/durlobactam use.
鲍曼不动杆菌-醋酸钙不动杆菌复合体（ABC）感染给临床医生带来了困难，因为他们可用的有效抗菌药物有限。舒巴坦/多利培南为医院获得性肺炎和呼吸机相关性肺炎的易感菌株患者提供了一种新的治疗选择。
本文全面讨论了舒巴坦/多利培南，包括其基本特征、体外活性以及支持其用于治疗 ABC 的临床试验数据。本综述中使用了制造商的数据、迄今为止的已发表文献和会议数据。
舒巴坦/多利培南为临床医生提供了一种新的、有效的治疗耐药 ABC 感染的方法。舒巴坦与多利培南联合使用时，对 ABC 分离株的活性增强，这在临床试验和上市后病例研究中观察到了积极的临床结果。尽管迄今为止总体治疗指征和临床经验有限，但与其他药物相比，舒巴坦/多利培南具有相似的、有利的安全性。与联合抗生素治疗的使用相关的因素、商业药敏试验的可用性和成本效益，目前都是使用舒巴坦/多利培南的关键考虑因素。
